Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Femasys Inc. stock logo
FEMY
Femasys
$1.33
$1.61
$0.25
$4.75
$29.39M-3387,469 shs114,142 shs
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.33
-2.5%
$3.85
$2.70
$11.60
$8.82M2.2628,238 shs12,001 shs
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
$0.76
+7.0%
$1.03
$0.71
$23.00
$2.65M2.2432,662 shs7,339 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$2.76
+1.5%
$3.93
$2.60
$70.00
$14.99M0.11237,381 shs323,723 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Femasys Inc. stock logo
FEMY
Femasys
0.00%+2.31%-17.39%+66.25%+59.99%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-5.04%+21.29%+6.13%+41.97%-61.88%
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
+7.67%-0.70%-22.38%-41.63%-58.67%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
+1.47%-6.12%-7.38%-32.85%-92.03%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Femasys Inc. stock logo
FEMY
Femasys
2.3744 of 5 stars
3.52.00.00.02.62.50.6
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
1.7646 of 5 stars
3.55.00.00.00.00.00.0
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Femasys Inc. stock logo
FEMY
Femasys
3.00
Buy$11.33752.13% Upside
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
3.00
Buy$3.00292.36% Upside
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/A

Current Analyst Ratings

Latest NURO, FEMY, TTOO, and TNON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$5.00 ➝ $3.00
4/1/2024
Femasys Inc. stock logo
FEMY
Femasys
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
4/1/2024
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $12.00
3/21/2024
Femasys Inc. stock logo
FEMY
Femasys
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
3/21/2024
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/20/2024
Femasys Inc. stock logo
FEMY
Femasys
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Femasys Inc. stock logo
FEMY
Femasys
$1.07M27.47N/AN/A$0.85 per share1.56
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.46N/AN/A$13.18 per share0.33
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
$2.93M0.97N/AN/A$0.30 per share2.55
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.19M2.12N/AN/A($6.91) per share-0.40

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Femasys Inc. stock logo
FEMY
Femasys
-$14.25M-$0.92N/AN/AN/A-1,329.10%-105.47%-80.50%5/9/2024 (Estimated)
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
-$15.58M-$9.74N/AN/A-532.14%-934.11%-200.10%5/14/2024 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-696.19%N/A-129.79%5/28/2024 (Estimated)

Latest NURO, FEMY, TTOO, and TNON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Femasys Inc. stock logo
FEMY
Femasys
-$0.19-$0.19N/A-$0.19$0.30 million$0.21 million
3/12/2024Q4 2023
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
N/A-$0.68-$0.68-$0.68N/A$0.81 million
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Femasys Inc. stock logo
FEMY
Femasys
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Femasys Inc. stock logo
FEMY
Femasys
0.24
7.59
7.37
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
N/A
1.24
1.06
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.45
0.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Femasys Inc. stock logo
FEMY
Femasys
65.27%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
22.74%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
Femasys Inc. stock logo
FEMY
Femasys
16.39%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
7.30%
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
8.40%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Femasys Inc. stock logo
FEMY
Femasys
3222.10 million18.48 millionNot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.84 millionNot Optionable
Tenon Medical, Inc. stock logo
TNON
Tenon Medical
213.73 million3.41 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
1135.51 million5.51 millionOptionable

NURO, FEMY, TTOO, and TNON Headlines

SourceHeadline
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
globenewswire.com - April 24 at 9:00 AM
T2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head ContrastT2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head Contrast
americanbankingnews.com - April 22 at 1:26 AM
T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest UpdateT2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update
americanbankingnews.com - April 15 at 3:22 AM
T2 Biosystems converts $15M loan to equity, aims for Nasdaq complianceT2 Biosystems converts $15M loan to equity, aims for Nasdaq compliance
investing.com - April 13 at 6:55 PM
T2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
finanznachrichten.de - April 12 at 9:52 AM
T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
globenewswire.com - April 11 at 4:05 PM
T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
finanznachrichten.de - March 28 at 11:09 AM
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
globenewswire.com - March 28 at 9:00 AM
T2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
finanznachrichten.de - March 20 at 4:39 PM
T2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick FactsT2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick Facts
markets.businessinsider.com - March 20 at 4:39 PM
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
globenewswire.com - March 20 at 7:30 AM
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesT2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
globenewswire.com - March 19 at 9:00 AM
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
globenewswire.com - March 18 at 9:00 AM
TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq ComplianceTTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance
investorplace.com - March 12 at 3:16 PM
T2 Biosystems Receives Extension From Nasdaq to Comply With Listing RequirementT2 Biosystems Receives Extension From Nasdaq to Comply With Listing Requirement
360dx.com - March 12 at 10:40 AM
T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
finanznachrichten.de - March 12 at 10:40 AM
T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
globenewswire.com - March 12 at 9:00 AM
T2 Biosystems IncT2 Biosystems Inc
money.usnews.com - February 16 at 10:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 12:34 PM
T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call TranscriptT2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 16 at 12:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 11:09 AM
T2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaT2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
finanznachrichten.de - February 16 at 7:34 AM
Q4 2023 T2 Biosystems Inc Earnings CallQ4 2023 T2 Biosystems Inc Earnings Call
finance.yahoo.com - February 16 at 7:34 AM
T2 Biosystems Preliminary Q4 Revenues Down 69 PercentT2 Biosystems Preliminary Q4 Revenues Down 69 Percent
360dx.com - February 15 at 9:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Femasys logo

Femasys

NASDAQ:FEMY
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Tenon Medical logo

Tenon Medical

NASDAQ:TNON
Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as stabilizes and transfixes the SI joints. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
T2 Biosystems logo

T2 Biosystems

NASDAQ:TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.